NEXT GENERATION INVESTMENT BANKING

Members network
Limited Mobile Version
Follow this company and never miss a research update
KARO

Karo Pharma

Market Cap 3,590.7M
Today
Day High
43.80
43.7
Day Low
42.90
Day Open
43.30
Prev Close
43.70
VWAP
43.4
Volume
227K
Turnover
9.857M
Top Broker
VWAP
43.0
Avg Volume
241K
Avg Turnover
10.378M
Top Brokers
AVA/NON
VWAP
42.9
Avg Volume
493K
Avg Turnover
21.162M
Top Brokers
AVA/NON
VWAP
40.9
Avg Volume
441K
Avg Turnover
18.064M
Top Brokers
AVA/NON
52 week summary
Price Range
23.0
Last
44.8
Beta
N/A
Market Cap
3,590.7M
Total Return
76.9%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
82.2M
Next Earnings Date
24 Aug
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months 39.4%
Change 12 Months 44.0%
Volume Trend
Average Volume 10 vs 60 Days -35.7%
Price VS
52 Week High -2.5%
50 Day Moving Average 13.0%
200 Day moving Average 36.3%

Add article markers

Compare Karo Pharma to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Peter Blom, CEO
  • Executive board
  • Anders Lönner, Chairman of the board
Source: Millistream
Major Owners Equity Votes
Försäkringsaktiebolaget, Avanza Pension 8.9%
8.9%
Anders Lönner 5.6%
5.6%
JP Morgan Bank 4.4%
4.4%
Nordnet Pensionsförsäkring AB 3.4%
3.4%
Nomic AB 2.6%
2.6%
Source: Millistream
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
+ 0
0 Sales
- 0
Last 24 weeks
0 Purchases
+ 0
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.